At Avik Pharmaceutical, our vision for the future of healthcare is strongly rooted in the harmony between scientific innovation and environmental responsibility. Today, we are proud to highlight a milestone that reflects this philosophy — the publication of our international patent for a Biocatalytic Deacetylation System (BDS), an advanced green chemistry technology applied in the synthesis of Budesonide, an essential corticosteroid widely used in respiratory therapeutics.
Traditionally, the deacetylation steps in Budesonide synthesis depend on harsh chemical reagents, elevated temperatures, and environmentally unsafe solvents. Our BDS platform transforms this paradigm. By leveraging enzyme-based biocatalysis, we introduce a cleaner, more selective, and more energy-efficient pathway that significantly reduces the ecological footprint of the manufacturing process.
The advantages speak for themselves:
- Substantial reduction in chemical waste
- Enhanced reaction selectivity and process efficiency
- Lower energy consumption
- A safer working environment for operational teams
- Greener production of critical Budesonide intermediates
This achievement reaffirms our ongoing commitment to green chemistry principles and sustainable pharmaceutical manufacturing. It also showcases the dedication and expertise of our R&D and process development teams, whose relentless pursuit of innovation continues to propel Avik Pharmaceutical forward.
As we shape the next generation of API development and inhalation solutions, we remain committed to innovating responsibly and contributing to a more sustainable future for global healthcare.
